Main Body of the Abstract
Introduction:
Limited data are available on worsening renal function (wRF) in patients with ATTR-CA. We aim to investigate wRF and its associated clinical characteristics over one-year follow-up in patients diagnosed with ATTR.
Methods:
134 patients with a confirmed diagnosis of ATTR-CA were stratified into two groups: a group with maintained renal function (mRF, an increase in GFR or a decrease <10%) and a group with wRF (a drop of ≥ 10% in GFR) and compared using appropriate testing. Statistically significant (P<0.05) variables in the univariate analysis were included in the multivariable logistic regression model to determine characteristics associated with wRF.
Results:
Within a follow-up period of 326±118 days, 41.8% (n=56) had wRF, while the rest had mRF. When comparing the mRF and the wRF groups, patients with wRF were more likely African American (26.8% vs. 10.3%, P=0.01) and were less likely to have a history of ischemic heart disease (48.2% vs.71.8%, P=0.01) or CKD (55.4% vs. 71.8%, P=0.04), tended to present with NYHA class ≥III (66.1% vs. 47.4%, P=0.03) and were less likely to be on SGLT-2i (3.6% vs. 20.8%, P=0.002). On subsequent multivariable logistic regression, only NYHA class ≥III (OR: 3.9, 95% CI [1.6-9.3]), history of IHD (OR:0.3, 95% CI [0.1-0.7]), and receiving SGLT-2i (OR: 0.1, 95% CI [0.02-0.5]), were significant predictors of wRF.
Conclusion:
Almost 4 in 10 ATTR-CA patients had wRF during the first year following diagnosis. Not receiving SGLT-2i, worse NYHA class, and not having a history of IHD were significantly associated with renal dysfunction.

**Main Body of the Abstract**
Introduction:
Limited data are available on worsening renal function (wRF) in patients with ATTR-CA. We aim to investigate wRF and its associated clinical characteristics over one-year follow-up in patients diagnosed with ATTR.
Methods:
134 patients with a confirmed diagnosis of ATTR-CA were stratified into two groups: a group with maintained renal function (mRF, an increase in GFR or a decrease <10%) and a group with wRF (a drop of ≥ 10% in GFR) and compared using appropriate testing. Statistically significant (P<0.05) variables in the univariate analysis were included in the multivariable logistic regression model to determine characteristics associated with wRF.
Results:
Within a follow-up period of 326±118 days, 41.8% (n=56) had wRF, while the rest had mRF. When comparing the mRF and the wRF groups, patients with wRF were more likely African American (26.8% vs. 10.3%, P=0.01) and were less likely to have a history of ischemic heart disease (48.2% vs.71.8%, P=0.01) or CKD (55.4% vs. 71.8%, P=0.04), tended to present with NYHA class ≥III (66.1% vs. 47.4%, P=0.03) and were less likely to be on SGLT-2i (3.6% vs. 20.8%, P=0.002). On subsequent multivariable logistic regression, only NYHA class ≥III (OR: 3.9, 95% CI [1.6-9.3]), history of IHD (OR:0.3, 95% CI [0.1-0.7]), and receiving SGLT-2i (OR: 0.1, 95% CI [0.02-0.5]), were significant predictors of wRF.
Conclusion:
Almost 4 in 10 ATTR-CA patients had wRF during the first year following diagnosis. Not receiving SGLT-2i, worse NYHA class, and not having a history of IHD were significantly associated with renal dysfunction.

Predictors of Developing Renal Dysfunction Following Diagnosis of Transthyretin Cardiac Amyloidosis PC58 (#236)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.